Latest News

• Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

   

  Read more ...

• Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

   

  Read more ...

• Major conferences in San Francisco

  Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

  Read more ...

Media Coverage

• July 15, 2020 – European Biotechnology Magazine Summer 2020: Antiviral drug for pandemic preparedness (page 29)
• June 5, 2020 – Genetic Engineering & Biotechnology News: Atriva Therapeutics – ATR-002
• June 2, 2020 – Pharmazeutische Zeitung: MEK-Inhibitor im Test gegen Covid-19
• June 2020 – Nature Biopharma Dealmakers: Atriva Therapeutics: transforming antiviral therapies
• May 4, 2020 - Capital: Wirkt das? Biotech gegen Corona
• March 24, 2020 – ARD: Kampf um Corona-Medikamente
• February 6, 2020 – Handelsblatt: Wie Pharmakonzerne an Mitteln gegen das Coronavirus forschen
• January 28, 2020 – SCRIP: Atriva fast tracks antiviral candidate as coronavirus arrives in Germany 
• January 28, 2020 – Der Tagesspiegel: Therapieansätze gegen das Wuhan-Virus. Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren 
• July 7, 2019 – LABO: Vier Unternehmen mit "Biomarker Validation Award" ausgezeichnet 
• March 8, 2019 – Labiotech: Flu resistant to antivirals? This biotech has a drug for that
• January 4, 2019 – Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren
• 2017 – New article published in "Platform Life Sciences" presenting ATRIVA approach
• 2017 – Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017
• 2017 – Nature: Host with the most: Targeting host cells instead of pathogens to fight infectious disease

Events & Presentations

Please note that, due to the current coronavirus crisis, many conferences have been canceled or postponed.

Feel free to contact us any time.